Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

Mitsubishi Tanabe Pharma

Status and phase: Completed; Phase 2

Conditions: Diabetic Polyneuropathy

Treatments: Drug: Placebo; Drug: MCC-257

Study type: Interventional

Funder types: Industry

Identifiers

NCT00307749

MCC-257-A03

Details and patient eligibility

About

The primary objectives of the study are to evaluate the efficacy and safety of three doses of MCC-257 in patients with mild to moderate diabetic polyneuropathy

Full description

The study will use a double-blind, randomized, placebo-controlled, fixed-dose, parallel-group design. Patients will be randomized equally to 1 of 4 treatment groups: MCC-257 20 mg, MCC-257 40 mg, MCC-257 80 mg, or placebo, given once daily for 24 weeks. The study will consist of 2 periods: 1) a screening period of up to 21 days prior to baseline, including a formal screening visit; and 2) a 24-week treatment period, during which patients will take the study treatment, and have various assessments performed during 4 visits.

Enrollment: 420 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient is male or female, 18-70 years of age
• The patient has either type 1 or type 2 diabetes
• The patient has mild to moderate diabetic neuropathy
• The patient is free from other clinically significant illness or disease, as determined by medical history, physical examination, laboratory evaluations, and other safety tests

Exclusion criteria

• Being treated with anticoagulants other than aspirin, such as warfarin, digoxin, Plavix
• BMI>40
• A significant disorder or a condition other than diabetes that can cause symptoms or physical conditions that mimic peripheral neuropathy or interfere with cognition
• Any proximal neuropathy, clinically evident nerve entrapment, or any focal trauma potentially affecting nerve function
• Women of childbearing potential who do not refrain from sexual activity or use adequate contraception
• Pregnant or lactating women
• An ALT or AST value >2X upper limit of normal (ULN)
• Clinically significant cardiovascular disease within the last six (6) months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

420 participants in 4 patient groups, including a placebo group

1

Placebo Comparator group

Treatment:

Drug: Placebo

2

Experimental group

Treatment:

Drug: MCC-257

Drug: MCC-257

Drug: MCC-257

3

Experimental group

Treatment:

Drug: MCC-257

Drug: MCC-257

Drug: MCC-257

4

Experimental group

Treatment:

Drug: MCC-257

Drug: MCC-257

Drug: MCC-257